Semnur Pharmaceuticals, Inc.

Biotechnology • Healthcare • Palo Alto, CA, United States • SMNRW (PNK)

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

650 516 4310 960 San Antonio Road, Palo Alto, CA 94303, United States

Stock Performance (90 Days)

Data through Dec 22, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 2 - Yahoo Finance

Yahoo Finance • Sep 23

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combi - GlobeNewswire

GlobeNewswire • Sep 4

Scilex holding sells $200m in Semnur Pharmaceuticals shares - Investing.com

Investing.com • Sep 25

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside - Stocktwits

Stocktwits • Aug 21

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement - Yahoo Finance

Yahoo Finance • Aug 21

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Semnur Pharmaceuticals, Inc. had layoffs?

No layoff events have been recorded for Semnur Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Semnur Pharmaceuticals, Inc. have?

Semnur Pharmaceuticals, Inc. has approximately 3 employees.

What industry is Semnur Pharmaceuticals, Inc. in?

Semnur Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Semnur Pharmaceuticals, Inc. a publicly traded company?

Yes, Semnur Pharmaceuticals, Inc. is publicly traded under the ticker symbol SMNRW on the PNK.

Where is Semnur Pharmaceuticals, Inc. headquartered?

Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, CA, United States at 960 San Antonio Road, Palo Alto, CA 94303, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.